Jolkinolide B alleviates renal fibrosis via anti-inflammation and inhibition of epithelial-mesenchymal transition in unilateral ureteral obstruction mice

Abstract

Renal fibrosis is a critical pathological process lead to a progressive loss of renal function. Jolkinolide B (JB) is a natural compound with anti-inflammatory activity from Euphorbia fischeriana Steud. The study evaluated the effect of JB on renal fibrosis in mice with unilateral ureteral obstruction (UUO). The results showed that JB could decrease renal fibrotic area, reduce phosphorylation of NF-κB p65 and the release of TNF-α, IL-6 and IL-1β, restore the expression of vementin, α-SMA and E-cadherin, as well as TGF-β1 and p-smad2/3. In conclusion, JB might reduce renal fibrosis by inhibiting inflammation induced by NF-κB pathway and EMT mediated by TGF-β1/Smad pathway.

KEYWORDS:

• Jolkinolide B
• renal fibrosis
• inflammation
• epithelial-mesenchymal transition
• TGF-β1

Disclosure statement

The authors declare that they have no relevant financial interest.

Data availability statement

The data that support the findings of this study are openly available in “figshare” at https://doi.org/10.6084/m9.figshare.14775828 [DOI].

Additional information

Funding

This work was financially supported by National Natural Science Foundation of China (No. 82104483; 81872761; 81960633 and 81773958), Open project of the State Key Laboratory of Natural Medicine Active Substances and Functions (GTZK202001), G20 Engineering Innovation Research Project of Beijing Municipal Science & Technology Commission (No. Z181100002218029), and Elite Medical Professionals Open Project of China-Japan Friendship Hospital (No. ZRJY2021-BJ06; ZRJY2021-TD06).